MODERN APPROACH TO THE RETINOPATHY OF PREMATURITY TREATMENT
Sažetak
Retinopathy of prematurity is a proliferative retinopathy that occurs in prematurely born children. It is still the leading cause of preventable childhood blindness worldwide. The aim of this paper is to present the therapeutic modalities for the рetinopathy of prematurity. Current gold standard treatment is the laser photocoagulation of avascular retina in order to reduce its existing hypoxia. Expanding our knowledge of the pathogenesis of рetinopathy of prematurity, and the knowledge of the laser therapy efficiency and complications as well, new therapeutic options appear (intravitreal application of anti VEGF, gene therapy and administration of supplements). In order to avoid the visual function loss in prematures caused by retinopathy of prematurity, screening of the premature newborn is the first choice.
Key words: retinopathy of prematurity, anti VEGF, childhood blindness
Reference
Akçakaya AA, Yaylali SA, Erbil HH, Sadigov F et al. Screening fir Retinopathy of Prematurity in a Tertiary Hospital in Istanbul: Incidence and Risk Factors. J Pediatr Ophthalmol Strabismus 2012;49:21-25
Mutlu FM, Sarici SU. Retinopathy of prematurity: incidence and risk factors. Exprt Rev Ophthalmol. 2007; 2(2):267–274.
Palmer EA, Flynn JT, Hardy RJ, et al. Incidence and early course of retinopathy of prematurity: The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology. 1991; 98(11):1628–1640.
Hoogerwerf A, Schalij-Delfos NE, van Schooneveld MJ, Termote JUM. Incidence of retinopathy of prematurity over the last decade in the Central Netherlands. Neonatology. 2010; 98(2):137–142.
Phan MH, Nguyen PN, Reynolds JD. Incidence and severity of retinopathy of prematurity in Vietnam, a developing middle-income country. J Pediatr Ophthalmol Strabismus. 2003; 40(4):208–212.
Mutlu FM, Altinsoy HI, Mumcuoglu T, et al. Screening for retinopathy of prematurity in a tertiary care newborn unit in Turkey: frequency, outcomes, and risk factor analysis. J Pediatr Ophthalmol Strabismus. 2008; 45(5):291–298.
Gilbert C, Foster A. Childhood blindness in the context of VISION 2020—the right to sight. Bull World Health Organ. 2001; 79(3):227–232.
Heckmann M. Pathogenesis of retinopathy of prematurity. Ophthalmologe. 2008;105(12):1101-7.
María Ana Martínez Castellanos, Shulamit Schwartz, Gerardo García-Aguirre, Hugo Quiroz-Mercado. Short-term Outcome After Intravitreal Ranibizumab Injections for the Treatment of Retinopathy of Prematurity. Br J Ophthalmol. 2013; 97(7):816-819
Smith EL, Hard AL, Hellstrom. The Biology of Retinopathy of Prematurity: How Knowlwdge of Pathogenesis Guides Treatment. Clin Perinatol. 2013; 40(2): 201-214
Smith LE. Pathogenesis of retinopathy of prematurity. Semin Neonatol. 2003;8(6):469–473.
Young TL, Anthony DC, Pierce E, Foley E, Smith LE. Histopathology and vascular endothelial growth factor in untreated and diode laser-treatedretinopathy of prematurity. J AAPOS. 1997;1 (2):105–110.
Colakoğlu O, Taşkiran B, Colakoğlu G, et al. Serum insulin like growth factor-1 (IGF-1) and insulin like growth factor binding protein-3 (IGFBP-3) levels in liver cirrhosis. Turk J Gastroenterol. 2007;18(4):245-9
Serrano ML, Romero A, Cendales R, Sánchez-Gómez M, Bravo MM. Serum levels of insulin-like growth factor-I and -II and insulin-like growth factor binding protein 3 in women with squamous intraepithelial lesions and cervical cancer. Biomedica. 2006;26(2):258-68.
Gole AG, Ells AL, Katz X, Fielder AL et al. The International Classification of Retinopathy of Prematurity Revisited. Arch Ophthalmol. 2005;123(7):991-999
Sonmez K, Drenser KA, Capone A, Jr, Trese MT. Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology. 2008; 115(6):1065–1070.
Löfqvist C, Andersson E, Sigurdsson J, et al. Longitudinal postnatal weight and insulin-like growth factor I measurements in the prediction of retinopathy of prematurity. Arch Ophthalmol. 2006; 124(12):1711–1718.
Landers MB 3rd, Toth CA, Semple HC, Morse LS. Treatment of retinopathy of prematurity with argon laser photocoagulation. Arch Ophthalmol. 1992; 110(1):44-7.
Kanski JJ. Clinical Ophthalmology. 5th ed. Elsevier; 2003. p.473-478
Travassos A, Teixeira S, Ferreira P, et al. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Laser Imag. 2007; 38(3):233–237.
Chung EJ, Kim JH, Ahn HS, Koh HJ. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2007; 245(11):1727–1730.
Mintz-Hittner HA, Kuffel RR. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina. 2008; 28(6):831–838.
Altinsoy HI, Mutlu FM, Gungor R, Sarici SU. Combination of laser photocoagulation and intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging. 2010; 1–5. doi: 10.3928/15428877-20100215-03.
Lee JY, Chae JB, Yang SJ, Yoon YH, Kim JG. Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels. Graefes Arch Clin Exp Ophthalmol. 2010; 248(9):1257–1262.
Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011; 364(7):603–615.
de Graaf M, Breur JM, Raphaël MF, Vos M, Breugem CC, Pasmans SG. Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants. J Am Acad Dermatol. 2011; 65(2):320–327
Filippi L, Cavallaro G, Fiorini P,et al. Study protocol: safety and efficacy of propranolol in newborns with Retinopathy of Prematurity (PROP-ROP): ISRCTN18523491. BMC Pediatr. 2010; 10:83.
Hard AL, Hellstrom A. On the use of antiangiogenetic medications for retinopathy of prematurity. Acta Paediatr. 2011; 100(8):1063–1065.
Löfqvist C, Niklasson A, Engström E, et al. A pharmacokinetic and dosing study of intravenous insulin-like growth factor-I and IGF-binding protein-3 complex to preterm infants. Pediatr Res. 2009; 65(5):574–579.
Stahl A, Sapieha P, Connor KM, et al. Short communication: PPAR gamma mediates a direct antiangiogenic effect of omega 3-PUFAs in proliferative retinopathy. Circ Res. 2010; 107(4):495–500.
Johnson L, Quinn GE, Abbasi S, et al. Effect of sustained pharmacologic vitamin E levels on incidence and severity of retinopathy of prematurity: a controlled clinical trial. J Pediatr. 1989; 114(5):827–838.
Amadio M, Govoni S, Pascale A. Targeting VEGF in eye neovascularization: What's new?: A comprehensive review on current therapies and oligonucleotide-based interventions under development. Pharmacol Res. 2016; 103:253-69.
Autrata R, Krejcírová I, Senková K, Holoušová M, Doležel Z, Borek I. Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. Eur J Ophthalmol. 2012; 22(5):687–694.
Ramsey DJ, Haddock LJ, Young LH, Eliott D. Complications of subspecialty ophthalmic care: systemic complications from the intravitreal administration of agents that target the vascular endothelial growth factor pathway. Semin Ophthalmol. 2014; 29(5-6):263-75
Nuzzi R, Tridico F. Complications of Intravitreal Anti-VEGF Drugs: A Report on Our Personal Experience. J Clin Exp Ophthalmol 6:448
Rajvardhan Azad. Use of intravitreal anti-VEGF: Retinopathy of prematurity surgeons’ in Hamlet's dilemma? Indian J Ophthalmol. 2011; 59(6): 421–422.
Bancalari A, Schade R, Muñoz T, Lazcano C, Parada R, Peña R. Oral propranolol in early stages of retinopathy of prematurity. J Perinat Med. 2016; 44(5):499-503
Greenblatt DJ, Koch-Weser J. Adverse reactions to propranolol in hospitalized medical patients: a report from the Boston Collaborative Drug Surveillance Program. Am Heart J 86 (1973): 478-84
Chowers I, Banin E, Hemo Y, et al. Gene transfer by viral vectors into blood vessels in a rat model of retinopathy of prematurity. Br J Ophthalmol. 2001; 85(8):991–995.
Ioannou PA, Vadolas J. Human Gene Therapy: Risks and Safety Considerations. Published Online: 27 jan 2006. DOI: 10.1038/npg.els.0003946
Hunt S. Increased dietary intake of omega-3-PUFA reduces pathological retinal angiogenesis. Ophthalmologe. 2007; 104(8):727–729.
Chen J, Connor KM, Aderman CM, Willett KL, Aspegren OP, Smith LE. Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. Invest Ophthalmol Vis Sci. 2009; 50(3):1329–1335.
Smith LE, Shen W, Perruzzi C,et al. Regulation of vascular endothelial growth factor dependent retinal neo-vascularization by insulin-like growth factor-1 receptor. Nat Med. 1999; 5(12):1390–1395.
Bhola R, Purkiss T, Hunter S, Stewart D, Rychwalski PJ. Effect of granulocyte colony-stimulating factor on the incidence of threshold retinopathy of prematurity. JAAPOS. 2009; 13(5):450–453.
Johnson L, Bowen FW, Abbasi A et al. Relationship of prolonged pharmacologic serum levels of vitamin E to incidence of sepsis and necrotizing enterocolitis in infants with birth weight 1,500 grams or less. Pediatrics. 1985; 75:619-638